Savara Inc. (NASDAQ: SVRA) announced that Dave Lowrance will step down as chief financial and administrative officer effective July 15, 2026, for health-related reasons. The clinical-stage biopharmaceutical company said Robert Lutz will assume the combined role of chief operating and financial officer.

Lowrance served in his role for nearly ten years, guiding the company through capital raises, its Nasdaq listing, and advancing its late-stage pipeline. He will remain available to the company in an advisory capacity following his departure.

Lutz has served as Savara's chief operating officer since February 2023. He previously held chief financial and business officer positions at iBio Inc. and Strongbridge Biopharma plc, and held leadership roles at Shire Plc and Cinergy Corp. He began his career as a financial analyst at Goldman Sachs.

The administrative responsibilities previously handled by Lowrance will be distributed among members of the senior leadership team, according to the company's press release.

Savara focuses on rare respiratory diseases, with its lead program MOLBREEVI in Phase 3 development for autoimmune pulmonary alveolar proteinosis. MOLBREEVI is a recombinant human granulocyte-macrophage colony-stimulating factor delivered via an investigational nebulizer system.

Lutz holds a bachelor's degree in economics and computer science from Amherst College and an MBA from the Kellogg School of Management.